JCCG 活動情報 －論文投稿 2020 年―
（主）
：主論文

神経芽腫委員会（主）Iehara T, Yoneda A, Kikuta A, Muraji T, Tokiwa K, Takahashi H, Teramukai S, Takimoto T, Yagyu
S, Hosoi H, Tajiri T, JNBSG. A phase II JN-I-10 efficacy study of IDRF-based surgical decisions andstepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol.
BMC Pediatr. 20:212. 2020. PMID:32398048

腎腫瘍委員会（主）大植 孝治, 越永 從道, 野崎 美和子, 桑島 成子, 田中 祐吉, 大喜多 肇, 瀧本 哲也, 福本 弘二.
JCCG 腎腫瘍委員会報告 両側 Wilms 腫瘍臨床研究 RTBL14 の結果 希少疾患に対する臨床試験施行上の問題点. 日本小児血液・がん学会雑誌. 57:318. 2020.

肝腫瘍委員会Fujiyoshi S, Honda S, Minato M, Ara M, Suzuki H, Hiyama E, Taketomi A. Hypermethylation of CSF3R isa novel cisplatin resistance marker and predictor of response to postoperative chemotherapy inhepatoblastoma. Hepatol Res. 50:598. 2020. PMID:31894653
Haeberle B, Rangaswami A, Krailo M, Czauderna P, Hiyama E, Maibach R, Lopez-Terrada D, Aronson DC,Alaggio R, Ansari M, Malogolowkin MH, Perilongo G, O'Neill AF, Trobaugh-Lotrario AD, Watanabe K,Schmid I, von Schweinitz D, Ranganathan S, Yoshimura K, Hishiki T, Tanaka Y, Piao J, Feng Y, Rinaldi E,Saraceno D, Derosa M, Meyers RL. The importance of age as prognostic factor for the outcome of patientswith hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC)
database. Pediatr Blood Cancer. 67:e28350. 2020. PMID:32383794（主）Hiyama E, Hishiki T, Watanabe K, Ida K, Ueda Y, Kurihara S, Yano M, Hoshino K, Yokoi A, TakamaY, Nogami Y, Taguchi T, Mori M, Kihira K, Miyazaki O, Fuji H, Honda S, Iehara T, Kazama T, Fujimura
J, Tanaka Y, Inoue T, Tajiri T, Kondo S, Oue T, Yoshimura K. Outcome and Late Complications of
Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor 2 Protocol. J Clin
Oncol. 38:2488. 2020. PMID:32421442

檜山 英三、兒島 正人、栗原 將、佐伯 勇. 国際共同臨床試験. 小児外科. 52:710. 2020.
Honda S, Chatterjee A, Leichter AL, Miyagi H, Minato M, Fujiyoshi S, Ara M, Kitagawa N, Tanaka M,Tanaka Y, Shinkai M, Hatanaka KC, Taketomi A, Eccles MR. A MicroRNA Cluster in the DLK1-DIO3
Imprinted Region on Chromosome 14q32.2 Is Dysregulated in Metastatic Hepatoblastomas. Front Oncol.
10:513601. 2020. PMID:33282720

ユーイング委員会（主）Chin M, Yokoyama R, Sumi M, Okita H, Kawai A, Hosono A, Koga Y, Sano H, Watanabe H, OzakiT, Mugishima H, Japan Ewing Sarcoma Study Group (JESS). Multimodal treatment including standard
chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing
sarcoma family of tumors in Japan: Results of the Japan Ewing Sarcoma Study 04. Pediatr Blood Cancer.
67:e28194. 2020. PMID:32077253
Umeda K, Miyamura T, Yamada K, Sano H, Hosono A, Sumi M, Okita H, Kamio T, Maeda N, Fujisaki H,Jyoko R, Watanabe A, Hosoya Y, Hasegawa D, Takenaka S, Nakagawa S, Chin M, Ozaki T, Japan Ewing
Sarcoma Study Group. Prognostic and therapeutic factors influencing the clinical outcome of metastaticEwing sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.
Pediatr Blood Cancer. 68:e28844. 2020. PMID:33340261

リンパ腫委員会
Kada A, Fukano R, Mori T, Kamei M, Tanaka F, Ueyama J, Sekimizu M, Osumi T, Mori T, Koga Y, OhkiK, Fujita N, Mitsui T, Saito AM, Hashimoto H, Kobayashi R. A Multicenter, Open-label, Clinical Trial toAssess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using
Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children. Acta
Med Okayama. 74:89. 2020. PMID:32099255

AML 委員会Hara Y, Shiba N, Yamato G, Ohki K, Tabuchi K, Sotomatsu M, Tomizawa D, Kinoshita A, Arakawa H,Saito AM, Kiyokawa N, Tawa A, Horibe K, Taga T, Adachi S, Taki T, Hayashi Y. Patients aged less than 3years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. Br J
Haematol. 188:528. 2020. PMID:31612466

Terui K, Toki T, Taga T, Iwamoto S, Miyamura T, Hasegawa D, Moritake H, Hama A, Nakashima K,Kanezaki R, Kudo K, Saito AM, Horibe K, Adachi S, Tomizawa D, Ito E. Highly sensitive detection ofGATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sangerand targeted next generation sequencing. Genes Chromosomes Cancer. 59:160. 2020. PMID:31606922
Saito Y, Sawa D, Kinoshita M, Yamada A, Kamimura S, Suekane A, Ogoh H, Matsuo H, Adachi S, Taga T,Tomizawa D, Osato M, Soga T, Morishita K, Moritake H. EVI1 triggers metabolic reprogramming
associated with leukemogenesis and increases sensitivity to L-asparaginase. Haematologica. 105:2118. 2020.
PMID:31649131
Matsuo H, Yoshida K, Nakatani K, Harata Y, Higashitani M, Ito Y, Kamikubo Y, Shiozawa Y, Shiraishi Y,Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Kiyokawa N, Tomizawa D, Taga T, Tawa A,Miyano S, Meggendorfer M, Haferlach C, Ogawa S, Adachi S. Fusion partner-specific mutation profiles
and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Blood Adv. 4:4623. 2020.
PMID:32991719（主）Hasegawa D, Tawa A, Tomizawa D, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, ShimadaA, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Miyachi H,Horibe K, Nakahata T, Adachi S. Attempts to optimize postinduction treatment in childhood acute myeloid
leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study
Group (JPLSG). Pediatr Blood Cancer. 67:e28692. 2020. PMID:32886449

再発 ALL 委員会（主）Kumamoto T, Goto H, Ogawa C, Hori T, Deguchi T, Araki T, Saito AM, Manabe A, Horibe K,Toyoda H. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic
leukemia in children: a report from Japan Children's Cancer Group. Int J Hematol. 112:720. 2020.
PMID:32761462

HLH/LCH 委員会
塩田曜子. 組織球系腫瘍の診断と治療. 日本臨牀. 78:708. 2020
Hayase T, Saito S, Shioda Y, Imamura T, Watanabe K, Ohki K, Yoshioka T, Oh Y, Kawahara Y, Niijima H,Imashuku S, Morimoto A. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell

histiocytosis in Japan. Int J Hematol. 112:560. 2020. PMID:32654047
森本哲. ランゲルハンス細胞組織球症 ～その細胞起源と細胞活性化機構. 炎症と免疫. 28:106. 2020.

ALL 委員会
Sakaguchi K, Imamura T, Ishimaru S, Imai C, Shimonodan H, Fujita N, Okada K, Taketani T, Kanai R,Tauchi H, Kato M, Kojima Y, Watanabe A, Deguchi T, Hashii Y, Kiyokawa N, Taki T, Saito AM, Horibe K,Manabe A, Sato A, Koh K. Nationwide study of pediatric B-cell precursor acute lymphoblastic leukemiawith chromosome 8q24/MYC rearrangement in Japan. Pediatr Blood Cancer. 67:e28341. 2020.
PMID:32323914（主）Tomizawa D, Miyamura T, Imamura T, Watanabe T, Moriya Saito A, Ogawa A, Takahashi Y,
Hirayama M, Taki T, Deguchi T, Hori T, Sanada M, Ohmori S, Haba M, Iguchi A, Arakawa Y, Koga Y,
Manabe A, Horibe K, Ishii E, Koh K.

A risk-stratified therapy for infants with acute lymphoblastic

leukemia: a report from the JPLSG MLL-10 trial. Blood. 136:1813. 2020. PMID:32845001

長期フォローアップ委員会（主）Sato I, Sato I, Soejima T, Ishida Y, Maeda M, Koh K, Kamibeppu K. Simple change in logistic
procedure improves response rate to QOL assessment: a report from the Japan Children's Cancer Group.
J Patient Rep Outcomes. 4:48. 2020. PMID:32556617（主）Nakajima S , Nakajima S, Sato I, Soejima T, Koh K, Kato M, Okamoto Y, Imamura T, Maeda M,Ishida Y, Manabe A, Kamibeppu K. Comparison of child and family reports of health-related quality of life
in pediatric acute lymphoblastic leukemia patients after induction therapy. BMC Pediatr. 20:390. 2020.
PMID:32814552

支持療法委員会
森尚子，加藤陽子，新小田雄一，大曽根眞也，嘉数真理子，佐野弘純，篠田邦大，矢野道広，石田裕二，斎藤雄弥，澤田明久，豊田秀実，足立壯一，福島啓太郎. 小児がん治療施設から見た緩和ケアの課題―JPLSG 施設調査より 第 1 報―. 日本小児血液・がん学会雑誌. 57:33. 2020.
加藤陽子，森 尚子，新小田雄一，大曽根眞也，嘉数真理子，佐野弘純，篠田邦大，矢野道広，石田裕二，

斎藤雄弥，澤田明久，豊田秀実，足立壯一，福島啓太郎. 小児がん患者に対する疼痛管理の現状と課題―JPLSG 施設調査より 第 2 報―. 日本小児血液・がん学会雑誌. 57:178. 2020.

遺伝性腫瘍委員会
中野嘉子. DICER1 症候群と遺伝性腫瘍. 遺伝性腫瘍, 20:124, 2020